Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exo… Read more
Market Cap & Net Worth: Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc (NASDAQ:SRPT) has a market capitalization of $1.80 Billion ($1.80 Billion) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5429 globally and #3196 in its home market, demonstrating a -2.83% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sarepta Therapeutics Inc's stock price $17.16 by its total outstanding shares 104787187 (104.79 Million).
Sarepta Therapeutics Inc Market Cap History: 2015 to 2026
Sarepta Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $4.04 Billion to $1.80 Billion (-4.40% CAGR).
Index Memberships
Sarepta Therapeutics Inc is a constituent of 5 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$862.21 Billion | 0.20% | #27 of 30 |
|
NASDAQ Health Care
IXHC
|
$2.20 Trillion | 0.08% | #143 of 976 |
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.01% | #639 of 3165 |
|
S&P Midcap 400
MID
|
$3.02 Trillion | 0.19% | #377 of 401 |
|
NASDAQ Biotechnology
NBI
|
$1.51 Trillion | 0.11% | #91 of 263 |
Weight: Sarepta Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sarepta Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sarepta Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.70x
Sarepta Therapeutics Inc's market cap is 6.70 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
54.16x
Sarepta Therapeutics Inc's market cap is 54.16 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $4.04 Billion | $1.25 Million | -$220.03 Million | 3226.41x | N/A |
| 2016 | $2.87 Billion | $5.42 Million | -$267.26 Million | 530.22x | N/A |
| 2017 | $5.83 Billion | $154.58 Million | -$50.69 Million | 37.72x | N/A |
| 2018 | $11.44 Billion | $301.03 Million | -$361.92 Million | 37.99x | N/A |
| 2019 | $13.52 Billion | $380.83 Million | -$715.08 Million | 35.51x | N/A |
| 2020 | $17.87 Billion | $540.10 Million | -$554.13 Million | 33.08x | N/A |
| 2021 | $9.44 Billion | $701.89 Million | -$418.78 Million | 13.44x | N/A |
| 2022 | $13.58 Billion | $933.01 Million | -$703.49 Million | 14.55x | N/A |
| 2023 | $10.10 Billion | $1.24 Billion | -$535.98 Million | 8.13x | N/A |
| 2024 | $12.74 Billion | $1.90 Billion | $235.24 Million | 6.70x | 54.16x |
Competitor Companies of SRPT by Market Capitalization
Companies near Sarepta Therapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Sarepta Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Sarepta Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Sarepta Therapeutics Inc's market cap moved from $4.04 Billion to $ 1.80 Billion, with a yearly change of -4.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.80 Billion | -20.26% |
| 2025 | $2.26 Billion | -82.30% |
| 2024 | $12.74 Billion | +26.09% |
| 2023 | $10.10 Billion | -25.58% |
| 2022 | $13.58 Billion | +43.90% |
| 2021 | $9.44 Billion | -47.18% |
| 2020 | $17.87 Billion | +32.12% |
| 2019 | $13.52 Billion | +18.24% |
| 2018 | $11.44 Billion | +96.14% |
| 2017 | $5.83 Billion | +102.84% |
| 2016 | $2.87 Billion | -28.90% |
| 2015 | $4.04 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Sarepta Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.80 Billion USD |
| MoneyControl | $1.80 Billion USD |
| MarketWatch | $1.80 Billion USD |
| marketcap.company | $1.80 Billion USD |
| Reuters | $1.80 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.